Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer
Breast Cancer: From Bench to Personalized Medicine, Page: 87-112
2022
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures4
- Readers4
Book Chapter Description
Thousands of genes are there but BRCA1 and 2 are the most talked about and cited with reference to many common malignancies and in particular breast cancer. These genes have a pivotal role to repair DNA but their mutations either heritable or somatic enhance sensitivity to carcinogenic agents that damage DNA. Being highly penetrant, BRCA1/2 furnishes access to various DNA damage pathways and aberrant cell cycle surge. Subsequent to the mutations in both genes, the impacted pathways augment the sensitivity to ionizing radiation coupled with condensed competence of the individual to restore the insult caused to DNA that consequently raise the vulnerability to breast carcinogenesis. Especially acquaintance with the prototype of inheritance of disease with reference to BRCA gene mutation manifests its distinctive feature to identify families that harbor the mutation that facilitate their therapeutic preventative measures to guard against the disease. Classification and revelation of BRCA mutation-affected patients manipulate the options for treatment and impact the outcome of breast cancer survival, and in addition could be a vital tool to identify their kins that harbor the inherited mutated gene. Therefore, these mutations highly implicated in breast cancer are actionable in the era of personalized medicine to treat the patients that prolong their survival outcome and free the patients from disease. Thus, it is imperative to develop and opt for the screening methods best available to identify the BRCA 1/2 mutations.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160477570&origin=inward; http://dx.doi.org/10.1007/978-981-19-0197-3_5; https://link.springer.com/10.1007/978-981-19-0197-3_5; https://dx.doi.org/10.1007/978-981-19-0197-3_5; https://link.springer.com/chapter/10.1007/978-981-19-0197-3_5
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know